MedTrace Logo

Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

NCT06101277 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2025-01-06

No results posted yet for this study

Summary

This is a phase 2 pragmatic study that evaluates the clinical benefit of continuing systemic therapy with the addition of locally ablative therapies for oligo-progressive solid tumors as the primary objective. The primary outcome measure is the time to treatment failure (defined as time to change in systemic failure or permanent discontinuation of therapy) following locally ablative therapy.

Conditions

  • Esophageal Cancer
  • Small Bowel Cancer
  • Gastroesophageal-junction Cancer
  • Gastric Cancer
  • Colorectal Cancer
  • Appendiceal Cancer
  • Biliary Cancer
  • Gall Bladder Cancer
  • Intrahepatic Cholangiocarcinoma
  • Extrahepatic Cholangiocarcinoma
  • Oligoprogressive

Interventions

DEVICE

Ablative local therapy

Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Edward Kim, MD, PhD · University of California, Davis

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-05
Primary Completion
2025-12-05
Completion
2031-01-05
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06101277 on ClinicalTrials.gov